JP2016532100A - アフィニティークロマトグラフィーマトリックス - Google Patents
アフィニティークロマトグラフィーマトリックス Download PDFInfo
- Publication number
- JP2016532100A JP2016532100A JP2016522848A JP2016522848A JP2016532100A JP 2016532100 A JP2016532100 A JP 2016532100A JP 2016522848 A JP2016522848 A JP 2016522848A JP 2016522848 A JP2016522848 A JP 2016522848A JP 2016532100 A JP2016532100 A JP 2016532100A
- Authority
- JP
- Japan
- Prior art keywords
- epitope
- blood group
- matrix
- oligosaccharide
- polymer particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
- A61K39/39525—Purification
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
- B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
- B01J20/26—Synthetic macromolecular compounds
- B01J20/265—Synthetic macromolecular compounds modified or post-treated polymers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/281—Sorbents specially adapted for preparative, analytical or investigative chromatography
- B01J20/286—Phases chemically bonded to a substrate, e.g. to silica or to polymers
- B01J20/289—Phases chemically bonded to a substrate, e.g. to silica or to polymers bonded via a spacer
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/281—Sorbents specially adapted for preparative, analytical or investigative chromatography
- B01J20/291—Gel sorbents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3214—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the method for obtaining this coating or impregnating
- B01J20/3217—Resulting in a chemical bond between the coating or impregnating layer and the carrier, support or substrate, e.g. a covalent bond
- B01J20/3219—Resulting in a chemical bond between the coating or impregnating layer and the carrier, support or substrate, e.g. a covalent bond involving a particular spacer or linking group, e.g. for attaching an active group
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
- B01J20/3244—Non-macromolecular compounds
- B01J20/3246—Non-macromolecular compounds having a well defined chemical structure
- B01J20/3248—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such
- B01J20/3251—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such comprising at least two different types of heteroatoms selected from nitrogen, oxygen or sulphur
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
- B01J20/3244—Non-macromolecular compounds
- B01J20/3246—Non-macromolecular compounds having a well defined chemical structure
- B01J20/3248—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such
- B01J20/3255—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such comprising a cyclic structure containing at least one of the heteroatoms nitrogen, oxygen or sulfur, e.g. heterocyclic or heteroaromatic structures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
- B01J20/3268—Macromolecular compounds
- B01J20/3272—Polymers obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds
- B01J20/3274—Proteins, nucleic acids, polysaccharides, antibodies or antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2220/00—Aspects relating to sorbent materials
- B01J2220/80—Aspects related to sorbents specially adapted for preparative, analytical or investigative chromatography
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Abstract
Description
本発明のマトリックスは、ポリマー粒子の支持体を含み、好ましくは、ゲル又は樹脂の形態にある。
本発明に従う支持体により保有されるリガンドは、天然では糖類である、血液型A又は血液型Bの抗原を表すオリゴ糖である。
リガンドは、リガンドを粒子へと結合させるスペーサーに、共有結合的に結合している。スペーサーは、立体障害を低減し、抗-A抗体及び抗-B抗体に対するリガンドの接近可能性を増大させて、これらに結合させる可能性をもたらす。
リガンドは、粒子とスペーサーとの間の共有結合、及びスペーサーとリガンドとの間の共有結合により、化学的に固定化する。
本明細書で規定されるマトリックスは、抗-A抗体及び/又は抗-B抗体に結合するアフィニティークロマトグラフィーにおいて有用である。
本発明のマトリックスを使用するアフィニティークロマトグラフィーは、調製物又は組成物中におそらく存在する、所望されない抗-A抗体及び/又は抗-B抗体を除去し、したがって治療的使用のための免疫グロブリンの濃縮物を調製することにより、免疫グロブリンのこれらの調製物又は組成物を精製するのに特に有利である。
a)例えば、エタノール分画及び/又はカプリル酸分画及び/又はクロマトグラフィー分離による、Ig組成物の調製、
b)Ig組成物の、本発明のマトリックス上のパーコレーションによる、イムノアフィニティークロマトグラフィー、並びに
c)生物学的安全性工程、好ましくは、夾雑するウイルス及び/又は粒子を除去するためのナノ濾過
で得ることができる。
クロマトグラフィー条件:
10±2g/LのIgGを含む、出願WO2002/092632において記載されている方法に従う分画により得られた免疫グロブリンの調製物を、産業スケールで、図2に例示される、血液型Aのエピトープに対応する三糖(N-アセチルガラクトサミン(GalNAc)-ガラクトース(Gal)-フコース)がグラフトされた架橋セルロースビーズ(「Iso A HyperCel」と称するゲル)と、図3に例示される、血液型Bのエピトープに対応する三糖(ガラクトース-ガラクトース-フコース)がグラフトされた架橋セルロースビーズ(「Iso B HyperCel」と称するゲル)との50/50混合物(v/v)を含むカラム上で実行される、抗-A/抗-Bアフィニティークロマトグラフィー工程にかける。
(ビーズ)-NH-C5H10-CO-NH-C3H6-(リガンド)
のスペーサーを介してビーズへとグラフトされる。グラフトされた三糖の密度は、マトリックスゲル1ml当たり0.3mgである。
カラムのフォーマット: D=0.5cm×5.1cm(カラムの容量(VC: volume of the column)=1ml)
接触時間: 2分
ロード: Aリガンド+Bリガンド1mg当たりの溶出調製物6g、すなわち、カラム1本当たりの製剤180ml。
収率は、洗浄及びパーコレーションの後、非吸着画分中のIgGを定量することにより決定した。アフィニティークロマトグラフィー工程の前の濃度に対する、最終調製物中に存在する抗-A同種凝集素及び抗-B同種凝集素の割合に対応する抗-A残留活性及び抗-B残留活性を、下記に記載される技法に従い、フローサイトメトリー(欧州薬局方により要求される希釈率の測定より高感度で正確な技法)により測定した。
得られたIgG収率並びに抗-A残留活性及び抗-B残留活性を、下記の表に示す。
Claims (17)
- 血液型A及び/又は血液型Bのエピトープに対応する少なくとも1つのオリゴ糖がグラフトされたポリマー粒子を含み、前記オリゴ糖が、スペーサーを介して、前記粒子へとグラフトされている、ゲルとしてのアフィニティークロマトグラフィーマトリックスであって、オリゴ糖の密度が、マトリックス1ml当たり0.2から0.7mgの間に含まれ、前記スペーサーが、式(I)-NH-R1-CO-NH-R2-[式中、R1は、C4〜C6アルキル基であり、R2は、C3〜C8アルキル基である]を有し、前記スペーサーが、そのアミン官能基を介して粒子に結合していることを特徴とするマトリックス。
- (i)血液型Aのエピトープに対応する少なくとも1つのオリゴ糖がグラフトされたポリマー粒子、及び/又は(ii)血液型Bのエピトープに対応する少なくとも1つのオリゴ糖がグラフトされたポリマー粒子を含む、請求項1に記載のマトリックス。
- (i)血液型Aのエピトープに対応する少なくとも1つのオリゴ糖がグラフトされたポリマー粒子、及び(ii)血液型Bのエピトープに対応する少なくとも1つのオリゴ糖がグラフトされたポリマー粒子を含む、請求項2に記載のマトリックス。
- 血液型Aのエピトープに対応する少なくとも1つのオリゴ糖、及び血液型Bのエピトープに対応する少なくとも1つのオリゴ糖の両方がグラフトされたポリマー粒子を含む、請求項1に記載のマトリックス。
- (i)血液型Aのエピトープに対応する少なくとも1つのオリゴ糖がグラフトされたポリマー粒子と、(ii)血液型Bのエピトープに対応する少なくとも1つのオリゴ糖がグラフトされたポリマー粒子と、(iii)血液型Aのエピトープに対応する少なくとも1つのオリゴ糖、及び血液型Bのエピトープに対応する少なくとも1つのオリゴ糖の両方がグラフトされたポリマー粒子との混合物を含む、請求項1に記載のマトリックス。
- オリゴ糖の密度が、マトリックス1ml当たり0.3から0.4mgの間に含まれ、好ましくは、マトリックス1ml当たり約0.3mgである、請求項1から5のいずれか一項に記載のマトリックス。
- 血液型Aのエピトープに対応するオリゴ糖及び/又は血液型Bのエピトープに対応するオリゴ糖が、三糖である、請求項1から6のいずれか一項に記載のマトリックス。
- 血液型Aのエピトープに対応するオリゴ糖が、三糖のN-アセチルガラクトサミン(GalNAc)-ガラクトース(Gal)-フコースである、請求項7に記載のマトリックス。
- 血液型Bのエピトープに対応するオリゴ糖が、オリゴ糖のガラクトース-ガラクトース-フコースである、請求項7に記載のマトリックス。
- R1が、C5アルキル基である、請求項1から9のいずれか一項に記載のマトリックス。
- R2が、C3アルキル基である、請求項1から10のいずれか一項に記載のマトリックス。
- 血液型Aのエピトープに対応する少なくとも1つのオリゴ糖がグラフトされたポリマー粒子と、血液型Bのエピトープに対応する少なくとも1つのオリゴ糖がグラフトされたポリマー粒子とが、25/75から75/25(v/v)、好ましくは、約50/50(v/v)の比率で混合されている、請求項3に記載のマトリックス。
- ポリマーが、架橋ポリマーである、請求項1から12のいずれか一項に記載のマトリックス。
- ポリマーが、セルロースであり、粒子が、好ましくは、多孔性のセルロースビーズである、請求項13に記載のマトリックス。
- 抗-A抗体及び/又は抗-B抗体に結合するアフィニティークロマトグラフィーにおける、請求項1から14のいずれか一項に記載のマトリックスの使用。
- 治療的使用のための免疫グロブリンG(IgG)を産業スケールで生産するための、請求項15に記載のマトリックスの使用。
- 治療的使用のための免疫グロブリンG(IgG)の濃縮物を調製するための方法であって、エタノール分画及び/又はカプリル酸分画及び/又はクロマトグラフィー分離によって、Ig組成物を血漿から得る工程と、請求項1から14のいずれか一項に記載のマトリックスを適用するアフィニティークロマトグラフィーを介して、組成物中におそらく存在する抗-A抗体及び/又は抗-B抗体を除去する工程とを含む方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1356635A FR3008097B1 (fr) | 2013-07-05 | 2013-07-05 | Matrice de chromatographie d'affinite |
FR1356636A FR3008098B1 (fr) | 2013-07-05 | 2013-07-05 | Matrice de chromatographie d'affinite a densite de ligands reduite |
FR1356635 | 2013-07-05 | ||
FR1356636 | 2013-07-05 | ||
PCT/FR2014/051734 WO2015001277A1 (fr) | 2013-07-05 | 2014-07-04 | Matrice de chromatographie d'affinité |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2016532100A true JP2016532100A (ja) | 2016-10-13 |
Family
ID=51303088
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016522848A Ceased JP2016532100A (ja) | 2013-07-05 | 2014-07-04 | アフィニティークロマトグラフィーマトリックス |
Country Status (13)
Country | Link |
---|---|
US (1) | US10611826B2 (ja) |
EP (1) | EP3016729B1 (ja) |
JP (1) | JP2016532100A (ja) |
KR (1) | KR20160029840A (ja) |
CN (1) | CN105358228A (ja) |
AU (1) | AU2014285971A1 (ja) |
CA (1) | CA2916566A1 (ja) |
ES (1) | ES2793176T3 (ja) |
IL (1) | IL243414A0 (ja) |
MX (1) | MX2016000063A (ja) |
PL (1) | PL3016729T3 (ja) |
TW (1) | TW201509432A (ja) |
WO (1) | WO2015001277A1 (ja) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6189751B2 (ja) | 2010-12-30 | 2017-08-30 | ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジーLaboratoire Francais du Fractionnement et des Biotechnologies | 病原体不活性化剤としてのグリコール |
MX2015010427A (es) | 2013-02-13 | 2016-03-17 | Lab Francais Du Fractionnement | Anticuerpos anti-tnf-alfa altamente galactosilados y sus usos. |
EP2956003A2 (en) | 2013-02-13 | 2015-12-23 | Laboratoire Français du Fractionnement et des Biotechnologies | Proteins with modified glycosylation and methods of production thereof |
MX2016000063A (es) | 2013-07-05 | 2016-03-01 | Lab Francais Du Fractionnement | Matriz de cromatografia de afinidad. |
FR3026950A1 (fr) * | 2014-10-09 | 2016-04-15 | Lab Francais Du Fractionnement | Procede de preparation de plasma universel |
US10697982B2 (en) | 2015-09-08 | 2020-06-30 | Merck Patent Gmbh | Methods of evaluating quality of a chromatography media which binds anti-A or anti-B antibodies |
US10697983B2 (en) | 2015-09-08 | 2020-06-30 | Merck Patent Gmbh | Methods of evaluating quality of media suitable for removing anti-A or anti-B antibodies |
US20170066839A1 (en) * | 2015-09-08 | 2017-03-09 | Merck Patent Gmbh | Novel affinity chromatography media for removal of anti-a and/or anti-b antibodies |
EP3592759A1 (en) | 2017-03-07 | 2020-01-15 | JMVA Biotech AB | Modified adsorptive surfaces |
JP7026116B2 (ja) * | 2017-08-23 | 2022-02-25 | Jsr株式会社 | クロマトグラフィー用担体、リガンド固定担体、クロマトグラフィーカラム、標的物質の精製方法、及びクロマトグラフィー用担体の製造方法 |
CN108101981B (zh) * | 2018-01-15 | 2019-06-04 | 四川远大蜀阳药业有限责任公司 | 一种静注免疫球蛋白的生产工艺 |
JP2022509734A (ja) * | 2018-12-05 | 2022-01-24 | サイトソーベンツ・コーポレーション | ヒトの血漿及び全血から抗a及び/又は抗b抗体を除去するための架橋多糖ベースの吸収剤 |
WO2024091525A1 (en) * | 2022-10-25 | 2024-05-02 | Donaldson Company, Inc. | Separation media and purification methods for blood antibodies using the same |
WO2024091527A1 (en) * | 2022-10-25 | 2024-05-02 | Donaldson Company, Inc. | Separation media and purification methods for carbohydrate containing molecules using the same |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01155943A (ja) * | 1987-11-10 | 1989-06-19 | Biocarb Ab | ゲル生成物の製造方法 |
US20040242857A1 (en) * | 1996-12-23 | 2004-12-02 | Kurt Nilsson | Filtration material |
JP2009521520A (ja) * | 2005-12-26 | 2009-06-04 | ラボラトゥワール・フランセ・ドゥ・フラクションマン・エ・デ・ビオテクノロジー・ソシエテ・アノニム | 抗Aおよび抗B抗体、ならびに多反応性IgGが減少した免疫グロブリンG(IgG)濃縮物 |
US20100152425A1 (en) * | 2007-05-04 | 2010-06-17 | Nilsson Kurt G I | Material for Separation of a Biomolecule |
EP2556848A1 (en) * | 2011-08-08 | 2013-02-13 | Gambro Lundia AB | Separation material comprising saccharide ligands |
WO2013066251A1 (en) * | 2011-10-30 | 2013-05-10 | Glycorex Ab | Method for the reduction or elimination of one or more components from a blood product |
Family Cites Families (119)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3519558A (en) | 1968-02-15 | 1970-07-07 | Abcor Inc | Separation of similar solutes using a semipermeable membrane |
BE759625A (fr) | 1969-12-10 | 1971-04-30 | Molkereigenossenschaft Dahlenb | Procede et dispositif pour la dialyse du lait, en particulier pour l'obtention de l'albumine du lait et du petit-lait |
CH566798A5 (ja) | 1973-05-29 | 1975-09-30 | Battelle Memorial Institute | |
SE396017B (sv) | 1974-12-23 | 1977-09-05 | Alfa Laval Ab | Filtreringsforfarande, serskilt for ultrafiltrering |
US4351710A (en) | 1980-01-10 | 1982-09-28 | Ionics, Incorporated | Fractionation of protein mixtures |
US4350156A (en) | 1980-05-29 | 1982-09-21 | Japan Foundation For Artificial Organs | Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid |
JPS583705B2 (ja) | 1980-07-18 | 1983-01-22 | 川澄化学工業株式会社 | 二重ロ過型血漿分離交換装置 |
US4420398A (en) | 1981-08-13 | 1983-12-13 | American National Red Cross | Filteration method for cell produced antiviral substances |
US4764369A (en) | 1983-07-14 | 1988-08-16 | New York Blood Center Inc. | Undenatured virus-free biologically active protein derivatives |
US4888115A (en) | 1983-12-29 | 1989-12-19 | Cuno, Incorporated | Cross-flow filtration |
CA1244349A (en) | 1985-06-26 | 1988-11-08 | Jen-Chang Hsia | Purification of hemoglobin and modified hemoglobin by affinity chromatography |
US4789482A (en) | 1986-02-10 | 1988-12-06 | Millipore Corporation | Method for separating liquid compositions on the basis of molecular weight |
US6727405B1 (en) | 1986-04-09 | 2004-04-27 | Genzyme Corporation | Transgenic animals secreting desired proteins into milk |
DE122007000007I2 (de) | 1986-04-09 | 2010-12-30 | Genzyme Corp | Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern |
ES2037273T3 (es) | 1987-04-11 | 1993-06-16 | Ciba-Geigy Ag | Proceso de focalizacion isoelectrica y medios para llevar a cabo dicho proceso. |
US5948441A (en) | 1988-03-07 | 1999-09-07 | The Liposome Company, Inc. | Method for size separation of particles |
US5256294A (en) | 1990-09-17 | 1993-10-26 | Genentech, Inc. | Tangential flow filtration process and apparatus |
US5648253A (en) | 1990-12-20 | 1997-07-15 | Tsi Corporation | Inhibitor-resistant urokinase |
US6448469B1 (en) | 1991-10-02 | 2002-09-10 | Genzyme Corporation | Production of membrane proteins in the milk of transgenic nonhuman mammals |
EP0804070B1 (en) | 1993-03-09 | 2000-05-24 | Genzyme Corporation | Process of isolation of proteins from milk |
FR2706466B1 (fr) * | 1993-06-14 | 1995-08-25 | Aetsrn | Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré. |
DE4326665C2 (de) | 1993-08-09 | 1995-07-13 | Biotest Pharma Gmbh | Verfahren zur Sterilfiltration von Milch |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US5518624A (en) | 1994-05-06 | 1996-05-21 | Illinois Water Treatment, Inc. | Ultra pure water filtration |
US5843705A (en) | 1995-02-21 | 1998-12-01 | Genzyme Transgenic Corporation | Transgenically produced antithrombin III |
US5597486A (en) | 1995-05-01 | 1997-01-28 | Millipore Investment Holdings Limited | Membrane filtration with optimized addition of second liquid to maximize flux |
EP0871671A1 (en) | 1995-09-07 | 1998-10-21 | PPL Therapeutics (Scotland) Limited | Purification of alpha-1 proteinase inhibitor |
US6054051A (en) | 1996-01-17 | 2000-04-25 | Genentech, Inc. | Tangential-flow filtration system |
US6268487B1 (en) | 1996-05-13 | 2001-07-31 | Genzyme Transgenics Corporation | Purification of biologically active peptides from milk |
US5868936A (en) * | 1996-06-20 | 1999-02-09 | Baxter International Inc. | Affinity membrane system and method of using same |
EP0973934A4 (en) | 1997-02-25 | 2003-02-05 | Genzyme Transgenics Corp | NON-SECRETED PROTEINS PRODUCED TRANSGENICALLY |
US6210736B1 (en) | 1997-06-17 | 2001-04-03 | Genzyme Transgenics Corporation | Transgenically produced prolactin |
KR20010031210A (ko) | 1997-10-20 | 2001-04-16 | 추후보정 | 세포계내의 mRNA량 및 단백질 발현을 증가시키는 방법및 변형 핵산 서열 |
SK288128B6 (sk) | 1998-06-09 | 2013-10-02 | Csl Behring Ag | Process for purifying immunoglobulin G (IgG), liquid immunoglobulin product and use thereof for the preparation of a medicament |
US20050181482A1 (en) | 2004-02-12 | 2005-08-18 | Meade Harry M. | Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk |
DE69933216T2 (de) | 1998-06-15 | 2007-09-20 | GTC Biotherapeutics, Inc., Framingham | Erythropoietin-analog-menschliches serum-albumin fusionsprotein |
US20030005468A1 (en) | 1998-06-19 | 2003-01-02 | Meade Harry M. | Methods and vectors for improving nucleic acid expression |
US20040117863A1 (en) | 1998-09-18 | 2004-06-17 | Edge Michael D. | Transgenically produced fusion proteins |
US6580017B1 (en) | 1998-11-02 | 2003-06-17 | Genzyme Transgenics Corporation | Methods of reconstructed goat embryo transfer |
EP1818397A1 (en) | 1998-11-02 | 2007-08-15 | Trustees Of Tufts College | Methods for cloning animals |
US20030177513A1 (en) | 1998-11-02 | 2003-09-18 | Yann Echelard | Transgenic and cloned mammals |
US7208576B2 (en) | 1999-01-06 | 2007-04-24 | Merrimack Pharmaceuticals, Inc. | Non-glycosylated human alpha-fetoprotein, methods of production, and uses thereof |
DK1154827T3 (da) | 1999-02-22 | 2007-02-19 | Ncsrt Inc | Oprensning af biologiske stoffer |
EP1162934A4 (en) | 1999-02-22 | 2005-01-26 | Eric F Bernstein | COMPOSITIONS AND METHODS FOR PREVENTING PHOTOVAGENING |
BR0014860A (pt) | 1999-10-14 | 2003-07-08 | Genzyme Transgenics Corp | Métodos para a produção de uma molécula alvo em um animal transgênico e purificação da molécula alvo |
US7544500B2 (en) | 1999-11-13 | 2009-06-09 | Talecris Biotherapeutics, Inc. | Process for the production of a reversibly inactive acidified plasmin composition |
MXPA02010907A (es) | 2000-05-05 | 2004-09-06 | Gtc Biotherapeutics Inc | Decorina producida transgenicamente. |
NZ523220A (en) | 2000-06-19 | 2005-03-24 | Gtc Biotherapeutics Inc | Transgenically produced platelet derived growth factor |
AU2001286445A1 (en) | 2000-08-10 | 2002-02-18 | Gtc Biotherapeutics, Inc. | Cryopreservation of sperm |
AU2001294175A1 (en) | 2000-10-06 | 2002-04-22 | Kyowa Hakko Kogyo Co. Ltd. | Method of purifying antibody |
US20040226052A1 (en) | 2000-10-13 | 2004-11-11 | Meade Harry M. | Methods of producing a target molecule in a transgenic animal and purification of the target molecule |
FR2824568B1 (fr) * | 2001-05-11 | 2004-04-09 | Lab Francais Du Fractionnement | Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique |
NZ529767A (en) | 2001-06-13 | 2005-10-28 | Taurus Hsa Llc | Purification of human serum albumin |
DE60232895D1 (de) | 2001-10-09 | 2009-08-20 | Mayo Foundation | Verwendung von agonistischen 4-1bb antikörpern zur erhöhung der immunantwort |
IL161855A0 (en) | 2001-11-28 | 2005-11-20 | Sandoz Ag | Chromatographic purification of recombinant human erythropoietin |
IL162528A0 (en) | 2002-01-11 | 2005-11-20 | Gtc Biotherapeutics Inc | Method and system for fusion and activation following nuclear transfer in reconstructed embryos |
US20040133931A1 (en) | 2003-01-08 | 2004-07-08 | Gavin William G. | Method and system for fusion and activation following nuclear transfer in reconstructed embryos |
ES2319636T3 (es) | 2002-02-05 | 2009-05-11 | Genentech, Inc. | Purificacion de proteinas. |
AU2003233428B2 (en) | 2002-04-01 | 2008-07-31 | The University Of Texas Medical Branch | Treatment of lung disorder |
WO2003085105A1 (en) | 2002-04-01 | 2003-10-16 | Gtc Biotherapeutics, Inc. | A method for selecting cell lines to be used for nuclear transfer in mammalian species |
US7323553B2 (en) | 2002-04-26 | 2008-01-29 | Genentech, Inc. | Non-affinity purification of proteins |
CN1688603A (zh) | 2002-07-15 | 2005-10-26 | 马约医学教育与研究基金会 | 使用4-1bb结合剂的治疗和预防 |
CA2501415A1 (en) | 2002-08-01 | 2004-02-12 | Gtc Biotherapeutics, Inc. | Method of selecting cells for somatic cell nuclear transfer |
US20040092719A1 (en) | 2002-09-17 | 2004-05-13 | Eszter Birck-Wilson | Isolation of immunoglobulin molecules that lack inter-heavy chain disulfide bonds |
US7264728B2 (en) | 2002-10-01 | 2007-09-04 | Dow Corning Corporation | Method of separating components in a sample using silane-treated silica filter media |
JP2006513170A (ja) | 2002-11-18 | 2006-04-20 | トーラス エイチエスエイ エルエルシー | 酸および塩基から溶液を連続的に自動混合する方法 |
US7087719B2 (en) | 2002-11-19 | 2006-08-08 | Gtc Biotherapeutics, Inc. | Method for the crystallization of human serum albumin |
AU2003298787A1 (en) | 2002-11-27 | 2004-06-23 | Gtc Biotherapeutics, Inc. | Modified antibodies stably produced in milk and methods of producing same |
EP1578192A4 (en) | 2002-12-10 | 2006-03-29 | Gtc Biotherapeutics Inc | METHOD AND SYSTEM FOR USING SOMATIC CELL CELL NUCLEAR TRANSFER EMBRYOS AS CELL DONORS FOR ADDITIONAL NUCLEAR TRANSFER |
US20040167320A1 (en) | 2003-02-24 | 2004-08-26 | Couto Daniel E. | Methods of tangential flow filtration and an apparatus therefore |
US7550263B2 (en) | 2003-09-05 | 2009-06-23 | Gtc Biotherapeutics, Inc. | Method for the production of fusion proteins in transgenic mammal milk |
CA2538722A1 (en) | 2003-09-15 | 2005-04-28 | Gtc Biotherapeutics, Inc. | Expression of dominant negative transmembrane receptors in the milk of transgenic animals |
BRPI0415887B1 (pt) | 2003-10-27 | 2021-01-26 | Wyeth | métodos para a remoção de agregados de elevado peso molecular utilizando cromatografia de hidroxiapatita |
US20050169908A1 (en) | 2004-01-23 | 2005-08-04 | Kazunori Murakami | Use of aerosolized antithrombin to treat acute lung injury |
US20050186608A1 (en) | 2004-02-19 | 2005-08-25 | Olsen Byron V. | Method for the production of transgenic proteins useful in the treatment of obesity and diabetes |
US20050192226A1 (en) | 2004-02-20 | 2005-09-01 | Perenlei Enkhbaatar | Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants |
US20050197496A1 (en) | 2004-03-04 | 2005-09-08 | Gtc Biotherapeutics, Inc. | Methods of protein fractionation using high performance tangential flow filtration |
US20050245444A1 (en) | 2004-04-30 | 2005-11-03 | Yann Echelard | Method of using recombinant human antithrombin for neurocognitive disorders |
US20060121004A1 (en) | 2004-12-07 | 2006-06-08 | Yann Echelard | Methods of reducing the incidence of rejection in tissue transplantation through the use of recombinant human antithrombin |
US20060123500A1 (en) | 2004-12-07 | 2006-06-08 | Gtc Biotherapeutics, Inc. | Methods of prescreening cells for nuclear transfer procedures |
US20060130159A1 (en) | 2004-12-09 | 2006-06-15 | Nick Masiello | Method of purifying recombinant MSP 1-42 derived from Plasmodium falciparum |
US20060168671A1 (en) | 2005-01-21 | 2006-07-27 | Gavin William G | Injection of caprine sperm factor (cSF), phospholipase C zeta (PLCzeta) and adenophostin A as alternative methods of activation during nuclear transfer in the caprine species |
US20080019905A9 (en) | 2005-02-18 | 2008-01-24 | Strome Scott E | Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection |
US20060182744A1 (en) | 2005-02-15 | 2006-08-17 | Strome Scott E | Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof |
DE102005007372A1 (de) * | 2005-02-17 | 2006-08-24 | Fresenius Medical Care Deutschland Gmbh | Vorrichtung zur Eliminierung von Substanzen aus Flüssigkeiten, insbesondere Blut |
US20060286548A1 (en) | 2005-06-16 | 2006-12-21 | Gregory Liposky | Method of making recombinant human antibodies for use in biosensor technology |
EP2388274A1 (en) | 2005-06-17 | 2011-11-23 | Janssen Alzheimer Immunotherapy | Methods of purifying anti A Beta antibodies |
WO2007014244A2 (en) | 2005-07-25 | 2007-02-01 | Gtc Biotherapeutics, Inc. | Method of purifying recombinant human antithrombin to enhance the viral and prion safety profile |
AU2006304886B2 (en) | 2005-10-21 | 2012-04-12 | Genzyme Corporation | Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use |
AU2013200440B2 (en) | 2005-12-26 | 2016-03-31 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Immunoglobulin G (IgG) concentrate depleted of anti-A and anti-B antibodies and of polyreactive IgGs |
US7531632B2 (en) | 2006-02-16 | 2009-05-12 | Gtc Biotherapeutics, Inc. | Clarification of transgenic milk using depth filtration |
WO2007124019A2 (en) | 2006-04-21 | 2007-11-01 | Gtc Biotherapeutics, Inc. | Methods and products related to the transfer of molecules from blood to the mammary gland |
FR2901796A1 (fr) | 2006-05-31 | 2007-12-07 | Lab Francais Du Fractionnement | Procede d'extraction d'une ou de plusieurs proteines presentes dans du lait |
WO2008073620A2 (en) | 2006-11-02 | 2008-06-19 | Neose Technologies, Inc. | Manufacturing process for the production of polypeptides expressed in insect cell-lines |
WO2009134389A2 (en) | 2008-05-01 | 2009-11-05 | Gtc Biotherapeutics, Inc. | An anti-cd137 antibody as an agent in the treatment of inflammatory conditions |
CN102187227B (zh) | 2008-09-15 | 2014-04-02 | Emd密理博公司 | 定量蛋白质系亲和色谱树脂的蛋白质泄露的方法 |
US20110082083A1 (en) | 2009-04-10 | 2011-04-07 | Gtc Biotherapeutics, Inc. | Formulations of liquid stable antithrombin |
JP6189751B2 (ja) | 2010-12-30 | 2017-08-30 | ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジーLaboratoire Francais du Fractionnement et des Biotechnologies | 病原体不活性化剤としてのグリコール |
JP6178311B2 (ja) | 2011-07-07 | 2017-08-09 | エルエフビー ユーエスエー インコーポレイテッドLfb Usa, Inc. | タンパク質を安定化する製剤 |
JP6433786B2 (ja) | 2011-08-10 | 2018-12-05 | ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジーLaboratoire Francais du Fractionnement et des Biotechnologies | 高度ガラクトシル化抗体 |
US8859840B2 (en) * | 2011-09-08 | 2014-10-14 | Cynthia Katsingris | Multiple-use blood blotting devices for diabetics for use when monitoring blood glucose levels |
CA2858825A1 (en) | 2011-12-19 | 2013-06-27 | Lfb Usa, Inc. | Recombinant human alpha-1-antitrypsin for the treatment of inflammatory disorders |
TW201400499A (zh) | 2012-03-12 | 2014-01-01 | Revo Biolog Inc | 抗凝血酶用於治療妊娠毒血症之用途 |
US9511087B2 (en) | 2012-08-03 | 2016-12-06 | Revo Biologics, Inc. | Use of antithrombin in extracorporeal membrane oxygenation |
WO2014040024A1 (en) | 2012-09-10 | 2014-03-13 | Revo Biologics, Inc. | The use of antibodies in treating hiv infection and suppressing hiv transmission |
JP2016513105A (ja) | 2013-02-13 | 2016-05-12 | ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジーLaboratoire Francais du Fractionnement et des Biotechnologies | 改変グリコシル化を有するセツキシマブおよびその使用 |
MX2015010427A (es) | 2013-02-13 | 2016-03-17 | Lab Francais Du Fractionnement | Anticuerpos anti-tnf-alfa altamente galactosilados y sus usos. |
EP2956003A2 (en) | 2013-02-13 | 2015-12-23 | Laboratoire Français du Fractionnement et des Biotechnologies | Proteins with modified glycosylation and methods of production thereof |
EP2956485A2 (en) | 2013-02-13 | 2015-12-23 | Laboratoire Français du Fractionnement et des Biotechnologies | Highly galactosylated anti-her2 antibodies and uses thereof |
FR3005576B1 (fr) | 2013-05-15 | 2015-06-19 | Lab Francais Du Fractionnement | Procede d'inactivation d'une proteine prion |
MX2016000063A (es) | 2013-07-05 | 2016-03-01 | Lab Francais Du Fractionnement | Matriz de cromatografia de afinidad. |
FR3015484A1 (fr) | 2013-12-20 | 2015-06-26 | Lab Francais Du Fractionnement | Proteines recombinantes possedant une activite de facteur h |
JP2017503490A (ja) | 2013-12-24 | 2017-02-02 | エルエフビー ユーエスエー インコーポレイテッドLfb Usa, Inc. | ヘパリンの遺伝子導入による製造 |
KR20170040132A (ko) | 2014-06-02 | 2017-04-12 | 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 | Fc 단편의 제조 |
FR3022462B1 (fr) | 2014-06-18 | 2018-04-27 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Composition orale d'anticorps anti-tnfalpha |
US20160158676A1 (en) | 2014-12-01 | 2016-06-09 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Method and apparatus for manipulating components of a filtration system |
US20180139938A1 (en) | 2015-05-04 | 2018-05-24 | Laboratoire Français du Fractionnement et des, Biotechnologies | Transgenic production of fc fusion proteins |
WO2016198641A1 (en) | 2015-06-12 | 2016-12-15 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Injectable composition of factor vii and fillers |
FR3038517B1 (fr) | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
-
2014
- 2014-07-04 MX MX2016000063A patent/MX2016000063A/es unknown
- 2014-07-04 JP JP2016522848A patent/JP2016532100A/ja not_active Ceased
- 2014-07-04 AU AU2014285971A patent/AU2014285971A1/en not_active Abandoned
- 2014-07-04 WO PCT/FR2014/051734 patent/WO2015001277A1/fr active Application Filing
- 2014-07-04 ES ES14750552T patent/ES2793176T3/es active Active
- 2014-07-04 CN CN201480038362.8A patent/CN105358228A/zh active Pending
- 2014-07-04 CA CA2916566A patent/CA2916566A1/fr not_active Abandoned
- 2014-07-04 TW TW103123198A patent/TW201509432A/zh unknown
- 2014-07-04 US US14/902,716 patent/US10611826B2/en active Active
- 2014-07-04 EP EP14750552.3A patent/EP3016729B1/fr active Active
- 2014-07-04 KR KR1020167003199A patent/KR20160029840A/ko not_active Application Discontinuation
- 2014-07-04 PL PL14750552T patent/PL3016729T3/pl unknown
-
2015
- 2015-12-30 IL IL243414A patent/IL243414A0/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01155943A (ja) * | 1987-11-10 | 1989-06-19 | Biocarb Ab | ゲル生成物の製造方法 |
US20040242857A1 (en) * | 1996-12-23 | 2004-12-02 | Kurt Nilsson | Filtration material |
JP2009521520A (ja) * | 2005-12-26 | 2009-06-04 | ラボラトゥワール・フランセ・ドゥ・フラクションマン・エ・デ・ビオテクノロジー・ソシエテ・アノニム | 抗Aおよび抗B抗体、ならびに多反応性IgGが減少した免疫グロブリンG(IgG)濃縮物 |
US20100152425A1 (en) * | 2007-05-04 | 2010-06-17 | Nilsson Kurt G I | Material for Separation of a Biomolecule |
EP2556848A1 (en) * | 2011-08-08 | 2013-02-13 | Gambro Lundia AB | Separation material comprising saccharide ligands |
WO2013066251A1 (en) * | 2011-10-30 | 2013-05-10 | Glycorex Ab | Method for the reduction or elimination of one or more components from a blood product |
Also Published As
Publication number | Publication date |
---|---|
ES2793176T3 (es) | 2020-11-13 |
TW201509432A (zh) | 2015-03-16 |
CA2916566A1 (fr) | 2015-01-08 |
US10611826B2 (en) | 2020-04-07 |
KR20160029840A (ko) | 2016-03-15 |
AU2014285971A1 (en) | 2016-02-04 |
PL3016729T3 (pl) | 2020-09-07 |
EP3016729A1 (fr) | 2016-05-11 |
WO2015001277A1 (fr) | 2015-01-08 |
EP3016729B1 (fr) | 2020-03-25 |
CN105358228A (zh) | 2016-02-24 |
IL243414A0 (en) | 2016-02-29 |
MX2016000063A (es) | 2016-03-01 |
US20160168229A1 (en) | 2016-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016532100A (ja) | アフィニティークロマトグラフィーマトリックス | |
US4138287A (en) | Purifying and isolating method for hepatitis virus to use in preparing vaccine | |
US11667671B2 (en) | Separation method | |
KR101250095B1 (ko) | 항-A 및 항-B 항체 그리고 다중반응성 IgGs가 결핍된면역글로블린 G(IgG) 농축물 | |
US20010014649A1 (en) | Chromatography adsorbents utilizing mercapto heterocyclic ligands | |
JP6093772B2 (ja) | タンパク質の混合モードクロマトグラフィー精製用の固相 | |
WO2014003137A1 (ja) | 高アフィニティー抗体、及びその製造方法 | |
JPH0354959B2 (ja) | ||
FR3008097A1 (fr) | Matrice de chromatographie d'affinite | |
EP1224462A2 (en) | Isoagglutinin-depleted blood compositions and methods of making same | |
CN105579463B (zh) | 混合模式配体 | |
FR3008098A1 (fr) | Matrice de chromatographie d'affinite a densite de ligands reduite | |
TW200927254A (en) | Antibody production method | |
US11732004B2 (en) | Compositions and methods for simplified high efficiency isolation of proteins | |
JP2010070490A (ja) | 抗体の精製方法 | |
US8258270B2 (en) | Prevention of leaching of ligands from affinity-based purification systems | |
JP6236278B2 (ja) | 体液浄化デバイス用IgG型抗体吸着材 | |
WO1988007892A1 (en) | B lymphocyte separating material and body fluid clarifying material | |
Jones | Staphylococcal Protein A as an extracorporeal immunosorbent: theoretical and practical considerations | |
JP2010180170A (ja) | 抗体製造方法 | |
JPH0459797A (ja) | 抗体の精製法 | |
Tharakan et al. | Immune Adsorption Chromatography for Protein Purification | |
Olson | Pharmaceutical and Biotechnology Applications | |
KR20170077129A (ko) | 개선된 제조 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170608 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180316 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180402 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180702 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181217 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190306 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190325 |
|
A045 | Written measure of dismissal of application [lapsed due to lack of payment] |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20190729 |